PROGRAM OVERVIEW

We are thrilled to bring you three full days of CME/CE education from our expert thought leaders and moderators with our Summer of Lipids 2021 Meeting.  Each day will be filled with presentations, live Q&A sessions with our faculty, Expert Theaters, CME/CE Symposia and more.  By registering for this activity, you will receive continued access to the on-demand recordings of the lectures for 30 days following the meeting. We look forward to this exciting educational opportunity that will bring lipid specialists together from all around the world!

You may need to disable administrative overlay in your Drupal record

Edit Parent - PROGRAM (visibility Show)

Agenda


The Summer of Lipids Conference will be held using the EASTERN time zone.
Friday, June 4, 2021
9:50 - 10:00 AM Opening Remarks
10:00 - 11:25 AM Session I - Addressing Global Issues of Health Inequalities: Part One
10:00 - 10:05 AM Pre-Session Assessment

10:05 - 10:25 AM

Addressing Prevention within the Diverse Hispanic Population Eduardo Sanchez, MD, MPH
10:25 - 10:45 AM Barriers to Lifestyle Therapy in Rural Populations and an Rx for Improvement Ralph La Forge, MSc, CLS, FNLA
10:45 - 11:05 AM Implementing Telemedicine and Virtual Clinics Pam R. Taub, MD
11:05 - 11:25 AM Post-Session Assessment and Question & Answer Panel
11:25 - 11:30 AM Break
11:30 AM - 12:55 PM Session II - Addressing Global Issues of Health Inequalities: Part Two
11:30 - 11:35 AM Pre-Session Assessment
11:35 - 11:55 AM Focus on Cardiovascular Health in Women Judith Regensteiner, PhD
11:55 AM - 12:15 PM Providing Access to Rural Populations Elizabeth J. Jackson, MSN, CLS, FNLA
12:15 - 12:35 PM Roundtable Discussion
12:35 - 12:55 PM Post-Session Assessment and Question & Answer Panel
12:55 - 1:55 PM Expert Theater
1:55 - 3:30 PM Break
3:30 - 4:55 PM Session III – The Latest in Cardiovascular Nutrition
3:30 - 3:35 PM Pre-Session Assessment
3:35 - 3:55 PM Expanding Access to Nutritional Services Geeta Sikand, RD, MA, CDE, CLS, FNLA
3:55 - 4:15 PM Effect of Plant-based Dietary Patterns Lori Alexander, MSHS, RDN, CCRC, CLS, FNLA 
4:15 - 4:35 PM Roundtable Discussion
4:35 - 4:55 PM Post-Session Assessment and Question & Answer Panel
4:55 - 5:00 PM Break
5:00 - 6:10 PM

NLA-EAS 2021 Joint Educational Session Series

Women, Atherosclerosis, and Lipids: What is Different?

5:00 - 5:05 PM Pre-Session Assessment
5:05 - 5:15 PM From Risk Factors to Acute Coronary Syndrome in Women EAS: Lale Tokgözoğlu, MD, FACC, FESC
5:15 - 5:30 PM Gender Specific Risks in Women EAS: Jeanine Roeters van Lennep, MD, PhD
5:30 - 5:40 PM Calcium Scoring in Women: Is it Different? NLA: Laxmi Mehta, MD, FNLA
5:40 - 5:55 PM Lipid Lowering Therapy in Women NLA: Eugenia Gianos, MD, FNLA
5:55 - 6:10 PM LIVE Broadcast: Question & Answer with Audience and Post-Session Assessment
6:10 - 7:15 PM Virtual Welcome Reception
7:25 - 9:30 PM CME/CE Symposium: Dialogues from the Dais: Mechanisms of Cardiovascular Protection for Omega-3 Fatty Acids
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2021 Summer of Lipids Program. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
Saturday, June 5, 2021
8:00 - 10:00 AM CME/CE Symposium
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2021 Summer of Lipids Program. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
9:00 - 9:50 AM Exhibit Hall
9:50 - 10:00 AM Opening Remarks
10:00 - 11:45 AM Session IV - Clinical Trials: Part One
10:00 - 10:05 AM Pre-Session Assessment
10:05 - 10:25 AM Pragmatic Evaluation of Events and Benefits of Lipid-Lowering in Older Adults (PREVENTABLE) Karen P. Alexander, MD
10:25 - 10:45 AM Analysis of ORION Kevin C. Maki, PhD, CLS, FNLA
10:45 - 11:05 AM What’s Coming in the Pipeline? Harold E. Bays, MD, FNLA
11:05 - 11:25 AM What's New in HoFH and FCS? Christie M. Ballantyne, MD, FNLA
11:25 - 11:45 AM Post-Session Assessment and Question & Answer Panel  
11:45 AM - 12:20 PM Exhibit Hall
12:25 - 1:25 PM Session V - Clinical Trials: Part Two
12:25 - 12:30 PM Pre-Session Assessment
12:30 - 1:10 PM

Investigator Initiated Trials: Challenging Conventional Thinking in Study Inequalities

Michael J. Koren, MD
1:10 - 1:25 PM Post-Session Assessment and Question & Answer Panel
1:30 - 2:30 PM Expert Theater
2:35 - 4:00 PM Session VI - Special Challenges in Treating Children
2:35 - 2:40 PM Pre-Session Assessment
2:40 - 3:00 PM Children in Clinical Trials and Informed Consent Sarah de Ferranti, MD, MPH
3:00 - 3:20 PM The Role of Parents when Treating Children Don P. Wilson, MD, FNLA
3:20 - 3:40 PM Unique Ways to Educate Parents and Children Ann Liebeskind, MD, FNLA
3:40 - 4:00 PM Post-Session Assessment and Question & Answer Panel
4:00 - 4:30 PM Exhibit Hall
4:30 - 5:55 PM Session VII - The Strange and Unusual Stories in Lipid Management
4:30 - 4:35 PM Pre-Session Assessment
4:35 - 5:35 PM Panel Discussion with Lipid Legends

Panel: Vera A. Bittner, MD, MSPH, FNLA

          Antonio M. Gotto, MD, DPhil, FNLA

             Carl E. Orringer, MD, FNLA

5:35 - 5:55 PM Post-Session Assessment and Question & Answer Panel
Sunday, June 6, 2021
9:00 - 9:50 AM Exhibit Hall
9:50 - 10:00 AM Opening Remarks
10:00 - 11:25 AM Session VIII - Building a Solid Foundation for Lipid Management
10:00 - 10:05 AM Pre-Session Assessment
10:05 - 10:20 AM Overview of Atherosclerosis Daniel E. Soffer, MD, FNLA
10:20 - 10:35 AM Diet and Lifestyle Therapy for Lipid Management Carol Kirkpatrick, PhD, MPH, RDN, FNLA
10:35 - 10:50 AM Pharmacologic Therapy for Lipid Management Joseph J. Saseen, PharmD, CLS, FNLA
10:50 - 11:05 AM Guidelines for Lipid Management Ann Liebeskind, MD, FNLA
11:05 - 11:25 AM Post-Session Assessment and Question & Answer Panel
11:25 AM - 12:00 PM Exhibit Hall
12:00 - 1:00 PM Session IX - Ask the Experts Panel
12:00 - 12:05 PM Pre-Session Assessment
12:05 - 12:55 PM Audience Presents Case and Questions

Panel: Penny Kris-Etherton, PhD, RD, CLS, FAHA, FASN, FNLA

           Carl E. Orringer, MD, FNLA

           Joyce L. Ross, MSN, CRNP, CLS, FNLA

12:55 - 1:00 PM Post-Session Assessment
1:00 - 2:00 PM Expert Theater
2:00 - 2:50 PM Session X - Not Just a Pawn: The Value of a Clinical Lipid Specialist in Health Systems: Part One
2:00 - 2:05 PM Pre-Session Assessment
2:05 - 2:20 PM Role of Clinicians Then and Now Daniel E. Soffer, MD, FNLA
2:20 - 2:35 PM Banging the Brick Walls of Bureaucracy Nataliya Pyslar, MD, FNLA
2:35 - 2:50 PM Taking it Over the Finish Line: The Role of the Pharmacy Team Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
2:50 - 3:00 PM Break
3:00 - 4:30 PM Session XI - Not Just a Pawn: The Value of a Clinical Lipid Specialist in Health Systems: Part Two
3:00 - 3:20 PM Identifying the Uncommon with EMRs Zahid Ahmad, MD
3:20 - 3:40 PM Making a Difference in Improving Outcomes Srinath Adusmalli, MD, MSc
3:40 - 4:00 PM Guide to Starting a Lipid Clinic Alan S. Brown, MD, FNLA
4:00 - 4:30 PM Post-Session Assessment and Question & Answer Panel
4:30 - 4:45 PM NLA Business Meeting Business Meeting Materials

Accreditation Information


Target Audience

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity

Enduring Internet Activity

Educational Objectives

At the conclusion of this activity, all participants should be able to:

Session I – Addressing Global Issues of Health Inequalities: Part One

  • Recognize population differences that may impact clinical care.
  • Appraise current and emerging management options for special populations with dyslipidemia.
  • Describe best practices for using telemedicine in patient management.

Session II – Addressing Global Issues of Health Inequalities: Part Two

  • Discuss the efficacy and safety of hormonal therapies in the management of dyslipidemia and cardiovascular risk.
  • Recognize gender differences in risk that impact clinical care to reduce cardiovascular disease.

Session III – The Latest in Cardiovascular Nutrition

  • Describe the role of medical nutrition therapy in the treatment of dyslipidemia.
  • Outline the impact of various diets on cardiovascular risks.

NLA-EAS 2021 Joint Educational Session Series

  • Establish ACS risk management strategies that improve the care of women in primary and secondary prevention.
  • Outline sex-specific risk factors for ACS.
  • Establish criteria for the use of CAC scoring in the evaluation and classification of ACS risk in women.
  • Compare the relative effectiveness of existing and emerging lipid altering therapies in ACS risk management in women.

Session IV – Clinical Trials: Part One

  • Critically appraise current clinical trials and methods.
  • Discuss recent and ongoing clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention.

Session V – Clinical Trials: Part Two                                                  

  • Identify implications of recent trials for clinical management of patients with genetic disorders.
  • Describe barriers to effective recruiting of patients for clinical trials.

Session VI – Special Challenges in Treating Children

  • Identify issues in the management of children with dyslipidemia.
  • Determine opportunities for ensuring patients are well informed about treatment options for dyslipidemia.

Session VII – The Strange and Unusual Stories in Lipid Management

  • Evaluate the management of patients with dyslipidemia through case discussions.

Session VIII – The Patient’s Perspective

  • Discuss unique challenges to treatment of dyslipidemia from the patient’s perspective.

Session IX – Ask the Experts Panel

  • Discuss recent research impacting the future management of patients with dyslipidemia.

Session X – Not Just a Pawn: The Value of a Clinical Lipid Specialist in Health Systems: Part One

  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
  • Discuss efficient models of patient care, including operational issues, regulations, and referral strategies to run successful lipid clinics in various settings.

Session XI - Not Just a Pawn: The Value of a Clinical Lipid Specialist in Health Systems: Part Two

  • Discuss the potential role of health information technology in optimizing lipid management.
  • Discuss efficient models of outpatient care, including operational issues, regulations, and referral strategies to run successful lipid clinics in various settings.

 

CME/CE credit provided by the National Lipid Association. This activity has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit.

Ancillary Course


Foundations of Lipidology Course

Virtual, Live Course

Monday, June 7 • 9:00 AM – 6:35 PM ET

Tuesday, June 8 • 9:00 AM – 3:30 PM

$550 NLA Members, $950 Non-Members, $0 Trainees

 

Overview

The NLA's Foundations of Lipidology course provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice and prepare for advanced training.

This course is particularly useful to review core elements of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacist, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.

The Foundations of Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).

For additional information, click the course logo below.

 

Delete PROGRAM

Edit Parent - SPECIAL EVENTS (visibility Show)

Expert Theaters


How to efficiently get our patients to LDL-C goals – a call to action

Friday, June 4, 2021
12:55 - 1:55pm EST

"How to efficiently get our patients to LDL-C goals – a call to action" is a session on the urgency of getting patients to goal and the tools we already have to achieve this. 
The first talk of the session will be a presentation by Dr. Ballantyne on the rationale for combination therapy in managing cardiovascular risk covering the data on the benefits of and need to use combination therapy to treat LDL-C. 
The second talk will be a presentation by Dr. Toth to introduce a new FDA approved therapy: Roszet (rosuvastatin and ezetimibe) tablets.

Speakers:

Christie M. Ballantyne, MD, FNLA
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Peter P. Toth, MD, PhD, FCCP, FASPC, FAHA, FESC, FACC
Director of Preventative Cardiology
CGH Medical Center
Sterling, Illinois
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, Illinois
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
President, American Society for Preventive Cardiology

 

Hosted by Althera Pharmaceuticals

 

 

VASCEPA® (icosapent ethyl): Elevating the Standard of Care

Saturday, June 5, 2021
9:00 - 10:00am EST

There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.

Speaker: 

Alan S. Brown, MD, FACC, FAHA, FNLA, FASPC 

 

Hosted by Amarin Pharma, Inc.

 

 

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C

Saturday, June 5, 2021
1:30 - 2:30pm EST

The session will cover the following information:

  • Cardiovascular disease and its mortality and morbidity
  • Unique mechanism of action for two treatment options
  • Efficacy data for two treatment options

  • Safety data for two treatment options

  • Overview of the ongoing Outcomes trial

 

Speaker: 

James Underberg, MS, MD, FACP, FNLA 
Lipidology & Cardiovascular Disease Prevention 
Diplomate American Board of Clinical Lipidology 
Past-President National Lipid Association 
President American Board of Clinical Lipidology

 

Hosted by Esperion

 

 

EVKEEZA®​ (evinacumab-dgnb) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Sunday, June 6, 2021
1:00 - 2:00pm EST

Please join us for the Newly Approved Treatment of EVKEEZA® (evinacumab-dgnb) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH).  For more information on EVKEEZA® please visit www.evkeezahcp.com  

 

Speaker: 

James Underberg, MS, MD, FACP, FNLA 
Lipidology & Cardiovascular Disease Prevention 
Diplomate American Board of Clinical Lipidology 
Past-President National Lipid Association 
President American Board of Clinical Lipidology

 

This program is being hosted by Regeneron Pharmaceuticals, Inc.

Symposia


Dialogues from the Dais: Mechanisms of Cardiovascular Protection for Omega-3 Fatty Acids

Friday, June 4, 2021
7:25 - 9:30pm EST

As more than 15 professional societies, including the NLA, recommend the use of icosapent ethyl to treat ASCVD when triglyceride levels are >150 mg/dL, considerable questions remain. Are all omega-3 fatty acids the same? Are TG levels a biomarker, risk factor, and treatment target in ASCVD? What sets REDUCE-IT apart from other omega-3 trials? This interactive activity, featuring world-class experts in ASCVD and omega-3 fatty acids, provides a framework for a deeper understanding of the role of omega-3s in ASCVD management. You won’t want to miss all of the exciting new data that will be presented and discussed!

 

R. Preston Mason, PhD
Cardiovascular Division
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Scientific Director and Founder
Elucida Research
Beverly, MA

 

Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD

 

Peter Libby, MD, FACC
Cardiovascular Medicine Specialist
Brigham and Women's Hospital
Mallinckrodt Professor of Medicine
Harvard Medical School
Boston, MA

 

Hosted by Medtelligence

This activity is supported by educational funding provided by Amarin Pharma Inc.

Delete SPECIAL EVENTS


SCIENTIFIC MEETINGS CO-CHAIRS

Peter H. Jones, MD, FNLA

Program Planner
Associate Professor
Baylor College of Medicine
Houston, TX

Joseph J. Saseen, PharmD, CLS, FNLA

Program Planner
President, National Lipid Association

Professor and Vice Chair
Clinical & Academic Programs
Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
Skaggs School of Pharmacy
Aurora, CO



PROGRAM PLANNERS

Mary Katherine Cheeley, PharmD, CLS, FNLA

Clinical Pharmacist Specialist
Grady Health System
Atlanta, GA

Nihar R. Desai, MD, MPH

Associate Professor of Medicine
Yale School of Medicine
Associate Chief
Section of Cardiovascular Medicine
Yale New Haven Health System
New Haven, CT

Casey Elkins, DNP, MEd, NP-C, CLS, FNLA

Program Planner
Assistant Dean for Academic Affairs
Director, DNP Program
University of South Alabama
College of Nursing
Mobile, AL

Eugenia Gianos, MD, FNLA

System Director
Cardiovascular Prevention
Northwell Health
Director
Women's Cardiovascular Program
Lenox Hill Hospital
Associate Professor of Cardiology
Hofstra School of Medicine
New York, NY

Anne C. Goldberg, MD, FACP, FNLA

Committee Co-Chair
President, Foundation of the NLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Kevin C. Maki, PhD, CLS, FNLA

Executive Council Chair, National Lipid Association
Adjunct Professor
Department of Applied Health Science
School of Public Health
Indiana University
Bloomington, IN
Chief Scientist
Midwest Biomedical Research
Chicago, IL

James A. Underberg, MD, MS, FNLA

Past- President, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director
Bellevue Hospital Lipid Clinic
New York, NY

Lauren Williams, MCN, RD, LD

Clinical Dietitian II
Endocrinology - REACH Clinic
Cook Children’s Medical Center
Fort Worth, TX



FACULTY

Salim S. Virani, MD, PhD

Assistant Professor
Medicine-Atherosclerosis & Lipoprotein
Medicine - Cardiology
Baylor College of Medicine
Houston, TX

Peter W.F. Wilson, MD, FNLA

Professor of Medicine and Public Health
Emory University
Atlanta, GA

Karen E. Aspry, MD, MS, FNLA

Director, Lipid Clinic and Cardiovascular
  Disease Prevention Program
Lifespan Cardiovascular Institute
East Greenwich, RI

Christie M. Ballantyne, MD, FNLA

Committee Co-Chair
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Lynne T. Braun, PhD, CNP, CLS, FNLA

Professor, Colleges of Nursing and Medicine
Rush University
Nurse Practitioner
Rush Heart Center for Women
Rush University Medical Center
Chicago, IL

Angela L. Brown, MD

Associate Professor of Medicine
Division of Cardiology
Washington University School of Medicine
St. Louis, MO

Emily E. Brown, MGC, CGC

Certified Genetic Counselor
Center for Inherited Heart Disease
Johns Hopkins University
Baltimore, MD

 

 

 

Keith C. Ferdinand, MD, FNLA

Professor of Medicine
School of Medicine
Tulane University
New Orleans, LA

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

Program Planner
Director/Clinical Associate Professor
Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID

Kevin C. Maki, PhD, CLS, FNLA

Executive Council Chair, National Lipid Association
Adjunct Professor
Department of Applied Health Science
School of Public Health
Indiana University
Bloomington, IN
Chief Scientist
Midwest Biomedical Research
Chicago, IL

Kristina Petersen, PhD

Assistant Professor
Department of Nutritional Sciences
Texas Tech University
Lubbock, TX



Disclaimer


Lipid Bucks: Lipid Bucks can be applied on the checkout page.

Registration: Online registration and payment must be received no later than June 3, 2021. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By visiting the exhibit hall, attendee understands, agrees and consents to the sharing of attendee’s contact information with the participating companies.

Photography: Photographs and/or video may be taken as part of the registered event. By registering for this event, you grant the National Lipid Association full rights to use the images resulting from the photography/video filming and any reproductions or adaptations of the images for promotional purposes. This may include (but is not limited to), the right to use them in print and online platforms, social media, press releases and other outlets.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than June 3, 2021. There will be a $50 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.

Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.